BridgeBio

美国BridgeBio Oncology Therapeutics声称其 KRAS G12C 抑制剂 BBO-8520 可能比同类其他药物更具优势。
周三公布的Onkoras-101 I期临床试验结果显示， 排除干扰后，BBO-8520在二线治疗KRAS G12C突变型非小细胞肺癌能达到 58% 的ORR，对比安进的Lumakras（36% ORR）和BMS的Krazati（43% ORR），...

$BridgeBio(BBOT)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-25-277601  Act: 34  Size: 211 KB 网页链接

$BridgeBio(BBOT)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001193125-25-277834  Act: 34  Size: 10 MB 网页链接

$BridgeBio(BBOT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-317962  Size: 5 KB 网页链接

$BridgeBio(BBOT)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-26-005435  Act: 33  Size: 68 KB 网页链接

$BridgeBio(BBOT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-26-003027  Size: 5 KB 网页链接

$BridgeBio(BBOT)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-26-005428  Act: 33  Size: 1 MB 网页链接

$BridgeBio(BBOT)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000902664-25-004881  Act: 34  Size: 12 KB 网页链接

$BridgeBio(BBOT)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-26-005425  Act: 34  Size: 197 KB 网页链接

$BridgeBio(BBOT)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001104659-25-112512  Act: 34  Size: 18 KB 网页链接

$BridgeBio(BBOT)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-26-000904  Act: 33  Size: 190 KB 网页链接